IFNG and macrophage activation syndrome: The first of them is designed as a three-arm study, with the aim to evaluate the effectiveness and safety of anakinra or emapalumab (an anti-IFNγ monoclonal antibody used for MAS [72]) against the standard therapies, in patients with respiratory failure and clinical signs of MAS (NCT04324021)